Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380769113> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4380769113 abstract "Introduction: Although heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly common, targeted HFpEF therapies remain limited. Current evidence-based treatment options are modestly effective and provide limited symptom relief. Hypothesis: Cilostazol, a generic and oral phosphodiesterase type 3 (PDE-3) inhibitor, rapidly improves HF symptoms and serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in HFpEF patients with an ejection fraction of 50% or higher. Methods: A prospective, double-blind, n-of-1 study with three crossovers with unblinding at the 1-month endpoint was designed. Stable outpatients with HFpEF received either placebo twice daily or Cilostazol 100mg twice daily for one week followed by three weekly crossovers. HF symptoms were assessed each week using the Kansas City Heart Failure Questionnaire (KCCQ-12) and NT-proBNP levels were measured at the end of weeks one and four. Results: Preliminary data from the initial 11 participants are presented (six men and five women, mean age 67±13 years). The mean KCCQ-12 score was eight points higher with Cilostazol than placebo (47±12 vs. 39±12; p<0.05) (Figure 1A). Median NT-proBNP levels were lowered by 22% with Cilostazol compared to placebo (412 [293-1066] pg/dL vs. 659 [323-897] pg/dL; p<0.05) (Figure 1B). Conclusions: In this preliminary analysis of CLIP-HFpEF, treatment with Cilostazol led to a rapid alleviation of HF symptoms and a decline in NT-proBNP levels when compared to placebo. The results of CLIP-HFpEF suggest a marked benefit of Cilostazol in HFpEF patients. Further studies are needed to elucidate the mechanism and long-term clinical benefits of Cilostazol in patients with HFpEF." @default.
- W4380769113 created "2023-06-16" @default.
- W4380769113 creator A5005967499 @default.
- W4380769113 creator A5019949677 @default.
- W4380769113 creator A5040006947 @default.
- W4380769113 creator A5048860090 @default.
- W4380769113 creator A5052204193 @default.
- W4380769113 creator A5073817755 @default.
- W4380769113 creator A5091277376 @default.
- W4380769113 date "2022-11-08" @default.
- W4380769113 modified "2023-10-17" @default.
- W4380769113 title "Abstract 9543: Cilostazol Improves Symptom Scores and Lowers NT-proBNP in HFpEF Preliminary Results From the CLIP-HFpEF N-of-1 Study" @default.
- W4380769113 doi "https://doi.org/10.1161/circ.146.suppl_1.9543" @default.
- W4380769113 hasPublicationYear "2022" @default.
- W4380769113 type Work @default.
- W4380769113 citedByCount "0" @default.
- W4380769113 crossrefType "journal-article" @default.
- W4380769113 hasAuthorship W4380769113A5005967499 @default.
- W4380769113 hasAuthorship W4380769113A5019949677 @default.
- W4380769113 hasAuthorship W4380769113A5040006947 @default.
- W4380769113 hasAuthorship W4380769113A5048860090 @default.
- W4380769113 hasAuthorship W4380769113A5052204193 @default.
- W4380769113 hasAuthorship W4380769113A5073817755 @default.
- W4380769113 hasAuthorship W4380769113A5091277376 @default.
- W4380769113 hasConcept C126322002 @default.
- W4380769113 hasConcept C142724271 @default.
- W4380769113 hasConcept C164705383 @default.
- W4380769113 hasConcept C203092338 @default.
- W4380769113 hasConcept C204787440 @default.
- W4380769113 hasConcept C27081682 @default.
- W4380769113 hasConcept C2775915353 @default.
- W4380769113 hasConcept C2777099384 @default.
- W4380769113 hasConcept C2777628954 @default.
- W4380769113 hasConcept C2778198053 @default.
- W4380769113 hasConcept C2779820409 @default.
- W4380769113 hasConcept C535046627 @default.
- W4380769113 hasConcept C71924100 @default.
- W4380769113 hasConcept C78085059 @default.
- W4380769113 hasConceptScore W4380769113C126322002 @default.
- W4380769113 hasConceptScore W4380769113C142724271 @default.
- W4380769113 hasConceptScore W4380769113C164705383 @default.
- W4380769113 hasConceptScore W4380769113C203092338 @default.
- W4380769113 hasConceptScore W4380769113C204787440 @default.
- W4380769113 hasConceptScore W4380769113C27081682 @default.
- W4380769113 hasConceptScore W4380769113C2775915353 @default.
- W4380769113 hasConceptScore W4380769113C2777099384 @default.
- W4380769113 hasConceptScore W4380769113C2777628954 @default.
- W4380769113 hasConceptScore W4380769113C2778198053 @default.
- W4380769113 hasConceptScore W4380769113C2779820409 @default.
- W4380769113 hasConceptScore W4380769113C535046627 @default.
- W4380769113 hasConceptScore W4380769113C71924100 @default.
- W4380769113 hasConceptScore W4380769113C78085059 @default.
- W4380769113 hasIssue "Suppl_1" @default.
- W4380769113 hasLocation W43807691131 @default.
- W4380769113 hasOpenAccess W4380769113 @default.
- W4380769113 hasPrimaryLocation W43807691131 @default.
- W4380769113 hasRelatedWork W1975213526 @default.
- W4380769113 hasRelatedWork W2051712573 @default.
- W4380769113 hasRelatedWork W2376801220 @default.
- W4380769113 hasRelatedWork W2383671142 @default.
- W4380769113 hasRelatedWork W2779222010 @default.
- W4380769113 hasRelatedWork W2965474825 @default.
- W4380769113 hasRelatedWork W3108114471 @default.
- W4380769113 hasRelatedWork W3155674270 @default.
- W4380769113 hasRelatedWork W3165187768 @default.
- W4380769113 hasRelatedWork W4223470538 @default.
- W4380769113 hasVolume "146" @default.
- W4380769113 isParatext "false" @default.
- W4380769113 isRetracted "false" @default.
- W4380769113 workType "article" @default.